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ABSTRACT
Endothelial precursor cells (EPCs) cultured from adult bone marrow (BM) have been shown to mediate neovas-
culogenesis in murine models of vascular injury. We sought to directly compare umbilical cord blood (UCB)- and
BM-derived EPC surface phenotypes and in vivo functional capacity. UCB and BM EPCs derived from mononu-
clear cells (MNC) were phenotyped by surface staining for expression of stromal (Stro-1, CXCR4, CD105, and
CD73), endothelial (CD31, CD146, and vascular endothelial [VE]-cadherin), stem cell (CD34 and CD133), and
monocyte (CD14) surface markers and analyzed by flow cytometry. The nonobese diabetic/severe combined
immunodeficiency murine model of hind-limb ischemia was used to analyze the potential of MNCs and culture-
derived EPCs from UCB and BM to mediate neovasculogenesis. Histologic evaluation of the in vivo studies
included capillary density as a measure of neovascularization. Surface CXCR4 expression was notably higher on
UCB-derived EPCs (64.29%  7.41%) compared with BM (19.69%  5.49%; P  .021). Although the 2 sources
of EPCs were comparable in expression of endothelial and monocyte markers, BM-derived EPCs contained higher
proportions of cells expressing stromal cell markers (CD105 and CD73). Injection of UCB- or BM-derived EPCs
resulted in significantly improved perfusion as measured by laser Doppler imaging at days 7 and 14 after femoral
artery ligation in nonobese diabetic/severe combined immunodeficiency mice compared with controls (P < .05).
Injection of uncultured MNCs from BM or UCB showed no significant difference from control mice (P  .119; P
 .177). Tissue samples harvested from the lower calf muscle at day 28 demonstrated increased capillary densities
in mice receiving BM- or UCB-derived EPCs. In conclusion, we found that UCB and BM-derived EPCs differ in
CXCR4 expression and stromal surface markers but mediate equivalent neovasculogenesis in vivo as measured by
Doppler flow and histologic analyses.
© 2006 American Society for Blood and Marrow Transplantation
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5NTRODUCTION
Atherosclerotic cardiovascular disease is the leading
ause of morbidity and mortality in the United States
nd accounts for approximately 1 million deaths per
ear. Coronary artery disease, a pathologic process of
rterial luminal narrowing by atherosclerotic plaque that
esults in obstruction of blood ﬂow to the myocardium,
ccounts for approximately half of these deaths. In
004, approximately 1 million percutaneous coronary
nterventions and 500 000 coronary artery bypass
rafting procedures were performed; these restore
lood ﬂow to ischemic myocardium. Characteristics
f vessels inadequately treated include small caliber,
alciﬁcation, and lesions in the distal segments. Not
urprisingly, patients who receive complete revascular-
zation have improved rates of survival when compared
ith those incompletely revascularized [1]. Therefore,
reatment limitations may be signiﬁcant in patients
ho possess areas of viable myocardium jeopardized
y the impaired perfusion supplied by vessels that are
oor targets for conventional revascularization tech-
iques. Prior studies, primarily using adult bone mar-
ow (BM)–derived mononuclear cells (MNCs), point
o the efﬁcacy of cultured endothelial precursor cells
EPCs) in mediating neovascularization in vascular
schemic animal models [2-4]. Initial animals studies
uggest that such cells could potentially also be used to
epair ischemic or damaged cardiac tissue [5-8]. Clin-
cal trials using autologous BM- or circulating blood–
erived progenitor cells have illustrated the safety of
ell infusions in human cardiac patients [9-12].
The cellular mechanisms underlying vasculogenesis,
process in which EPCs differentiate in situ into mature
ndothelial cells [13], has been further clariﬁed over the
ast 7 years with the identiﬁcation of BM-derived circu-
ating EPCs shown to migrate to areas of ischemia and
articipate in neovascularization [2,14-21]. Although
asculogenesis was previously considered to occur only
n the embryo [22], transplantation of cultured marrow-
erived EPCs from human adults into rodent models of
oth myocardial and peripheral ischemia resulted in
vident postnatal vasculogenesis [2,3].
Umbilical cord blood (UCB), a robust source of
ematopoietic stem cells, has been extensively studied in
ematology clinical applications and is capable of regen-
rating the entire hematopoietic system in adult patients
23]. Several qualities of UCB render it potentially ad-
antageous for human therapeutic EPC applications for
ascular ischemia when compared with patient-derived
M, including a higher concentration of stem cells,
reater proliferative capacity, longer telomeres, a broad
LA repertoire, immune tolerance, and a lack of viral
ontamination [24,25]. Murohara et al. [26] have re-
ently derived EPCs from UCB and shown enhanced
erfusion and neovascularization in rodent models of
ascular ischemia. However, to date, no direct compar- q
86son of cellular characteristics and functionality of UCB-
nd BM-derived EPCs in mediating vasculogenesis in
esponse to ischemia has been performed. In this study,
e directly compared EPCs derived from UCB and BM
nd analyzed their surface phenotype and functionality
n neovascularization in a nonobese diabetic/severe com-
ined immunodeﬁciency (NOD/SCID) vascular injury
odel.
ATERIALS AND METHODS
ell Culture
Human UCB and adult BM from volunteer healthy
onors were collected according to institutional review
oard protocols, including informed consent. MNCs
ere isolated by density gradient centrifugation from
resh UCB or BM. MNCs were plated on ﬁbronectin-
oated tissue culture ﬂasks at a density of 4 to 6 
06/mL (UCB MNC) or 1 to 2 106/mL (BM MNC)
n EBM2 medium (Clonetics, Walkersville, MD) with
% fetal bovine serum and standard SingleQuot ad-
itives that included vascular endothelial growth fac-
or, ﬁbroblast growth factor, insulin-like growth fac-
or, hydrocortisone, ascorbic acid, and heparin, as
reviously described [3,27]. Nonadherent cells were
iscarded after 4 days of culture, and medium was
eplaced. EPCs were harvested at day 7 of culture for
haracterization before injection in study animals.
ssessment of Acetylated Low-Density Lipoprotein
ptake and Ulex europaeus–Lectin Binding
After 7 days of culture in endothelial conditions, cells
ere tested for uptake of 1,1’-dioctadecyl-3,3,3’,3’-tetra-
ethylindocarbocyanine perchlorate-labeled acetylated
ow-density lipoprotein (Molecular Probes, Eugene,
R) and adherence of ﬂuorescein isothiocyanate–con-
ugated Ulex europaeus lectin (UEA-lectin; Sigma Chem-
cal Companies, St. Louis, MO) and were visualized by
onfocal microscopy. After 7 days of culture, adherent
ells were incubated for 4 hours with 1,1’-dioctadecyl-
,3,3’,3’-tetramethylindocarbocyanine perchlorate-la-
eled acetylated low-density lipoprotein at 37°C. The
ultures were washed, ﬁxed with 1% formaldehyde for
0 minutes, and washed again with phosphate-buffered
aline (PBS). UEA-lectin was added at a concentration
f 10 g/mL and incubated for 1 hour at 25°C. For
uclear detection, Hoechst 33258 (Sigma Chemical
ompanies) was added at 3 g/mL for 10 minutes.
ultures were then washed twice with PBS and visu-
lized with confocal microscopy. Thereafter, culture
lates were washed twice with PBS and incubated with
mmol/L ethylenediaminetetraacetic acid to remove
ells. The cells were washed and reconstituted in 1%
ormaldehyde and analyzed by ﬂow cytometry for
uantiﬁcation of ﬂuorescence.
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Bssessment of Surface Phenotype by Flow
ytometry of MNCs and EPCs
MNCs were characterized immediately after isola-
ion from UCB and BM. After 7 days of culture, adher-
nt cells were incubated with trypsin for 5 minutes at
7°C. Cells were then washed with PBS and counted.
he surface phenotype was evaluated by incubation for 20
inutes at 4°C with ﬂuorochrome-conjugated monoclo-
al antibodies: CD14, CD34, CD31, CD73 (Becton
ickinson, San Jose, CA), CD105 (Serotec, Raleigh,
C), CD133 (Miltenyi, Auburn, CA), CXCR4, Stro-1
R&D, Minneapolis, MN), CD146 (P1H12), and vascu-
ar endothelial (VE)-cadherin (Chemicon, Temecula,
A). Nonviable cells were excluded on the basis of
orward/side scatter, and no additional gating was ap-
lied. Positive-staining quadrants were set on non-
tained samples as a result of signiﬁcant autoﬂuores-
ence of cultured cells. An LSR ﬂow cytometer
Coulter, Miami, FL) was used that acquired 5000
uorescence events per sample. Compensation and
ata analysis were performed with WinList software
Verity Software House Inc., Topsham, ME).
xperimental Animals
Female NOD/SCID mice (Jackson Laboratories,
ar Harbor, ME) were anesthetized with intraperitoneal
njection of a combination of ketamine, acepromazine,
nd xylazine. To reduce immune-mediated rejection of
he injected cells by murine endogenous natural killer
ells, the mice were irradiated with a sublethal dose (2.5
y) from a cesium 137 source before human cell or
ontrol injections [28]. Blood ﬂow of the hind limbs was
easured with laser Doppler imaging (Laser ﬂow-meter
LF21D; Advance Company Ltd., Tokyo, Japan) for
aseline measurements. Under sterile conditions, a
mall skin incision was made in the right groin area.
he right femoral artery was exposed, ligated along
ith adjacent branches, and transected. The skin in-
ision was then closed with a continuous suture. Study
nimals then survived for 4 weeks. Blood ﬂow mea-
urements on both feet were repeated at 30 minutes
fter femoral artery ligation and at 7, 14, and 28 days
fter femoral ligation. All procedures were performed
n accordance with the policies of the Case Western
eserve University Institutional Animal Care and Use
ommittee.
ransplantation of Cells
After femoral artery ligation, the mice were random-
zed into 1 of 4 study groups. Group 1 (control) was
reated with intracardiac injection of culture medium or
ormal saline (0.3 mL), group 2 was treated with intra-
ardiac injection of cultured EPCs (106 in 0.3 mL of
ulture medium) from UCB, and group 3 received in-
racardiac injection of cultured EPCs (106 in 0.3 mL of
ulture medium) from adult BM. Group 4 mice were m
B&MTnjected with the starting material, BM or UCB MNC
106 in 0.3mL of culture medium). Intracardiac injection
as performed to avoid ﬁrst-pass uptake in lung and liver
esulting from an intravenous tail vein injection.
istologic Analysis
After 28 days, samples from the lower gastrocnemius
n both ischemic and healthy hind limbs were harvested
or capillary density determination and staining for hu-
an CD31. Capillary density was used as a measure of
eovascularization in addition to blood ﬂow [3,26,29-
1]. For this, fresh-frozen gastrocnemius transverse sec-
ions were stained for alkaline phosphatase to detect
apillary endothelial cells, as previously described [29].
rieﬂy, 12 fresh-frozen sections were cut (10-m thick-
ess) from each specimen and stained for alkaline phos-
hatase by using the indoxyl-tetrazolium method and
ounterstained with eosin to detect capillary endothelial
ells. Capillaries were counted with a40 objective by 2
ndependent investigators blinded to the study groups.
apillaries were counted in 20 ﬁelds per study animal,
nd 3 animals were evaluated for each study group.
Formalin-ﬁxed sections were mounted on saline-
oated glass slides and stained with anti-human CD31
ntibody (Dako, Glastrup, Denmark) to identify in-
orporation of human EPCs by staining. Cells positive
or human CD31 staining were counted in 5 high-power
elds by 2 blinded investigators. Sections from control
nimals were also stained with primary CD31 anti-
ody; no positive staining was noted, and this indi-
ated an absence of cross-reactivity with murine en-
othelial cells.
tatistical Analysis
Data are summarized by the mean  SEM. Statis-
ical signiﬁcance was determined between the indicated
alues by 2-tailed, nonpaired, unequal variance Student t
ests to determine differences between control and study
roup mean values. A value of P  .05 was considered
igniﬁcant. The Kruskal-Wallis test, a nonparametric
est based on Wilcoxon scores, was used if the normality
ssumption was violated.
ESULTS
n Vitro Characterization of UCB-
nd BM-Derived EPCs
After 1 week of culture, adherent cell yields from
CB cultures were on average 2.4%  0.3% of the
nitial MNC input, compared with 18.6%  2.2% ob-
ained from BM MNCs (Figure 1A; n  14). A median
f 18.7  107 MNCs (range, 2.80-68.7) were plated
rom single UCB units, and a median of 4.65  107
NCs (range, 6.0-14.3) were plated from 20 mL of
arrow aspirate cells. Comparable numbers of EPCs
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5ere harvested at day 7 comparing 1 UCB unit (3.0 
.4 106) and a 20-mL BM aspirate (4.9  0.9  106).
igure 1. Characteristics and yield of UCB- and BM-derived EPCs. M
nder endothelial conditions for 7 days [13]. Adherent cell yields at day
ompared with 18.6%  2.2% obtained from BM MNCs (A). Fluores
ow-density lipoprotein (acLDL; red) and nuclear staining with Hoech
ere taken at 40 with a Zeiss (Jena, Germany) LSM510 confocal
thylenediaminetetraacetic acid), and the ﬂuorescence of acetylated loFluorescent microscopy was used to evaluate the 1
88PC cell cultures (Figure 1B), and ﬂow cytometry was
sed to quantify ﬂuorescent microscopy results (Figure
clear cells (MNCs) from fresh UCB or BM were isolated and cultured
CB cultures were on average 2.4% 0.3% of the initial MNC input,
icroscopy of adherent cells was used to assess the uptake of acetylated
8 (blue) after 7 days of culture (B). Representative images shown here
cope. For ﬂow analysis, cultured cells were dissociated (2 mmol/L
ty lipoprotein and UEA-lectin was quantiﬁed (C).ononu
7 fromU
cent m
st 3325
microsC). UCB- and BM-cultured cells demonstrated a spin-
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UCB versus Marrow EPCs in Vascular Ischemia
Ble shape indicative of endothelial cell morphology. A
epresentative sample is shown in Figure 1. Binding of
EA-lectin, a marker of endothelial lineage, was similar
n cells cultured from UCB (71.9%) compared with
M-derived cells (81.9%). Most (92.4%) UCB-derived
PCs stained positive for uptake of acetylated low-den-
ity lipoprotein, whereas a smaller proportion (28.5%) of
M-derived EPCs were positive for acetylated low-den-
ity lipoprotein uptake (n  3). Double staining, indic-
tive of endothelial cell lineage [32], made up 60.7% of
he UCB-derived cells and 20.8% of the BM-derived
ells.
urface Phenotyping of UCB and BM MNCs
nd Cultured EPCs
Freshly isolatedMNCs fromUCB and BM and cells
ultured for 7 days were analyzed for expression of en-
othelial (CD146, CD31, and VE-cadherin), stromal
Stro-1, CXCR4, CD105, and CD73), stem cell (CD34
nd CD133), and monocyte (CD14) markers (n  3).
Expression of CD31 was comparable in both sources
f starting material: 26% in BM MNCs and 18% in
CB MNCs. The MNCs contained 8% positive CD14
n UCB and 9% in BM. UCB MNCs had a low expres-
ion of CD73 (5%) compared with BMMNCs (10%). A
mall percentage of the MNCs from UCB and BM
xhibited CD105 surface expression: 6% and 7%, re-
pectively. The expression of the stromal-derived fac-
or-1 (SDF-1) receptor CXCR4 on the UCB- MNCs
as 28%, and in BM MNCs it was 11%.
The data for the UCB- and BM-derived EPCs are
hown in Figure 2. Adherent cells were trypsinized and
ashed. Cells were stained for the endothelial-speciﬁc
igure 2. Flow cytometric analysis of EPC cells derived from UCB
ersus BM. UCB and BM MNCs were cultured for 7 days, and
dherent cells were trypsinized, washed, and stained for stromal
Stro-1, CXCR4, CD105, and CD73), endothelial (CD31, CD146,
nd VE-cadherin [VE-Cad]), stem cell (CD34 and CD133), andMonocyte (CD14) surface markers and analyzed by ﬂow cytometry.
B&MTarkers CD146 (P1H12, MUC18, or melanoma adhe-
ion molecule [MCAM]), CD31, and VE-cadherin.
imilar proportions of UCB and BM-derived EPCs
xpressed endothelial cell surface markers: 37% of the
ultured adherent cells from UCB- and 57% of BM-
erived EPCs stained positive for CD146 (P  .229).
fter the 7-day culture CD31 expression was present
n UCB (30%) and BM (29%), but there was not a
igniﬁcant difference between the 2 populations (P 
77). VE-cadherin was expressed in 15% of cells from
M, compared with 8% of cells from UCB (P .732).
s in the MNCs, after 7 days of culture, expression of
D14 remained low in UCB (2%) and BM (6%).
ultures from UCB showed greater expression of
tro-1, with 31% of UCB and 17% of BM having
ositive staining (P  .034). BM-derived EPCs exhib-
ted a higher expression of CD73 (44%) after culture
ompared with UCB (4%; P  .05). However, the
xpression of CD105 in BM EPCs increased to 40%
fter 7 days of culture, and this was signiﬁcantly
reater than the UCB EPCs (7%; P  .034). EPCs
erived from UCB also showed a signiﬁcantly higher
xpression of CXCR4 (64%) after 7 days of culture
ompared with BM-derived EPCs (20%; P  .021).
ransplantation of UCB- and BM-Derived EPCs
n an In Vivo Model
In vivo studies of neovascularization in the NOD/
CID hind-limb ischemia model were performed:
reshly isolated UCB- or BM MNCs and UCB- or
M-derived EPCs (adherent cells only) were harvested
t day 7 and given via an intracardiac injection (1  106
ells per mouse) after femoral artery ligation. Weekly
aser Doppler blood-ﬂow measurements were taken of
oth the injured and uninjured legs of all study animals.
he ratio of perfusion in the ischemic/healthy limb was
sed as an index of neovascularization in the study
roups. Baseline perfusion ratios were 0.994  0.019 (n
17) before ligation (data not shown). Immediately
fter femoral ligation, the perfusion ratios decreased to
.057  0.011 (control group), 0.031  0.008 (UCB
NCs), 0.039  0.008 (BM MNCs), 0.029  0.007
UCB-derived EPCs), and 0.020  0.003 (BM-derived
PCs), thus indicating reduced perfusion in all groups.
s shown in Figure 3, after 7 days, signiﬁcantly higher
erfusion ratios were noted when mice injected with
PCs were compared with control mice (P  .05).
igher perfusion ratios were measured in animals in-
ected with BM-derived EPCs compared with UCB-
erived EPCs (P  .045) at this early time point. A
ustained and signiﬁcant increase in blood ﬂow at day
4 was measured in mice injected with either human
M- or UCB-derived EPCs compared with the con-
rol mice. Perfusion ratios in the control and starting
aterial MNC groups remained low at day 14: 0.24
.032 (n  14; control), 0.25  0.032 (n  6; BM
NC), and 0.27  0.035 (n  8; UCB MNC) com-
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5ared with 0.41  0.031 (n  21) in the group that
eceived UCB-derived EPCs (P  .0008) and 0.48 
.039 (n  14) in the group that received BM-derived
PCs. It is important to note that at day 14 there was
o signiﬁcant difference in blood ﬂow between the 2
ources of EPCs (P  .18). No limb loss was observed
n any study animal during the 28 days of observation.
igure 3. Perfusion ratios after injection of EPCs into NOD/SCID
ice with induced hind-limb ischemia. NOD/SCID mice under-
ent femoral artery ligation and excision followed by intracardiac
njection of EPCs. Control animals were injected with saline or
omplete EBM2 media. Adherent UCB or BM EPCs on the day of
njection (day 7 of culture) were removed with trypsin, and 1  106
ells per mouse were injected. Doppler measurements were taken
mmediately after ligation and then on days 7, 14, and 28. Perfusion
atios were determined between the ischemic and nonischemic leg
f each study animal.
igure 4. Comparison of capillary density in treated and nontreate
issue was harvested from the lower calf muscle of study and control
ndoxyl-tetrazolium method. Two blinded investigators counted 2
quare millimeter.
90fter 28 days, perfusion ratios in control animals im-
roved to levels that approached those measured in
nimals treated with human cells.
istologic Analysis
Tissue from the lower calf muscles of both hind
imbs was harvested at day 28 for histologic evaluation.
apillary density was used as an additional evaluation of
eovascularization. Data from the 28-day time point are
hown in Figure 4. In the animals treated with EPCs
rom UCB, the density was signiﬁcantly increased: 103
6 capillaries per square millimeter (20 ﬁelds per ani-
al; 3 animals per group) versus 87  5 capillaries per
quare millimeter in control animals (P .035). Animals
hat received BM-derived EPCs also showed increased
apillary density compared with control mice (117  8
apillaries per square millimeter; P  .001). Figure 5
epicts the anatomic localization of EPCs derived from
uman cells in 28-day samples as identiﬁed by staining
ith anti-human CD31 antibody. Sections from mice
njected with human EPCs (UCB or BM) showed cells
xpressing human CD31 localized within the microvas-
ulature, whereas control femoral artery–ligated mice
emonstrated no cells that expressed human CD31.
ISCUSSION
Previous studies have demonstrated recovery of
PCs from UCB [26,33-36]. However, no direct com-
arison of UCB- and BM-derived EPCs, including cel-
ular characteristics and functionality, has been per-
ormed to date. Because UCB is a more readily available
llogeneic stem cell source than BM, it is important to
ddress whether UCB-derived EPCs have equivalent
. At 28 days after isolation and ligation of the right femoral artery,
Tissue was fresh-frozen and stained for alkaline phosphatase by the
per sample, and capillary density was expressed as capillaries perd mice
mice.
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UCB versus Marrow EPCs in Vascular Ischemia
BB&MTunctionality compared with BM-derived EPCs. We
herefore cultured EPCs from UCB and BM with stan-
ard conditions used for BM-derived EPCs and directly
ompared their potency in an in vivo murine model of
ind-limb ischemia.
Our studies directly comparing infusions of EPCs
ultured from nonselected UCB or BM MNCs revealed
quivalent biologic effects of increased blood ﬂow and
icrovascular density in the NOD/SCID study model
f hind-limb vascular injury. We observed that both
CB- and BM-derived EPC cell injections signiﬁcantly
ncreased blood ﬂow in the ischemic leg by days 7 and
4 after injury/cell injection.
To conﬁrm the neovascularization seen with
lood-ﬂow recovery, we evaluated the capillary den-
ity in histologic sections from treated animals. At day
8, capillary density was signiﬁcantly increased in an-
mals that received UCB- or BM-derived EPCs. Al-
hough we observed signiﬁcantly increased capillary
ensity in study animals treated with human cells, only
few detectable human CD31 cells were found an-
tomically incorporated in tissue distal to the site of
njury. These observations suggest possible paracrine
ffects mediated by injected human cells which con-
ribute to augmentation of microvascular density.
his interpretation is consistent with observations
ade by Kamihata et al. [7] that showed paracrine
ffects of BM MNCs implanted into ischemic myo-
ardium. A complex sequence of steps of paracrine
echanisms are coordinated in the development of
he adult vascular system [37]. Paracrine signaling
athways regulated by hypoxia elicit vascular endothe-
ial cell responses and vascular remodeling in ischemic
issue repair [38,39].
Despite equivalent biological effects of UCB- and
M-derived EPCs, we observed signiﬁcant differences
n the surface phenotype of injected cells. Whereas the
xpression of classic endothelial markers such as
D31, VE-cadherin, and CD146 was similar, the ex-
ression of CXCR4, the receptor for SDF-1, was
arkedly higher in UCB-derived cells. Expression of
his chemokine receptor may have implications in the
oming capacity of this cell population [40]. SDF-1
upports vasculogenesis, contributes to neovascular-
zation in vivo by augmenting cellular recruitment in
schemic tissues [30,40,41], and regulates endothelial
ell branching morphogenesis [42], thereby serving a
ritical role in vascular remodeling in ischemic tissue
43]. In the context of local tissue ischemia in the
OD/SCID hind-limb ligation model, increased mi-
ration of intracardiac-injected UCB-derived cells
oming to sites of hind-limb vascular injury may be
xpected to be facilitated because 64% of UCB-de-
ived cells express CXCR4, compared with only 20%
f BM-derived cells.
In contrast, expression of stromal markers (CD105igure 5.Histologic assessment of ischemic hind limbs with CD31.
issue from the lower calf muscles of both hind limbs was harvested
t day 28 for histologic evaluation. The samples were ﬁxed in
ormalin. Sections (6-m thickness) were mounted on saline-coated
lass slides and stained with anti-human CD31 antibody to identify
PCs derived from human cells. Control mice (A) were negative for
D31 staining. Specimens from mice that were injected with UCB-
erived EPCs (B) or BM-derived EPCs (C) showed positive stainingnd CD73) was signiﬁcantly higher in BM-derived cells
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5s compared with UCB-derived EPCs. Stromal cells
ontribute to the recruitment and proliferation of vascu-
ar network formation by promoting vascular growth by
irect cell-to-cell contact [44,45]. Enhanced expression
f stromal cell markers on BM-derived EPCs could
llow these cells to contribute to angiogenesis events in
hich new vessels arise by the migration and prolifera-
ion of endogenous endothelial cells from preexisting
essels [37]. Taken together, despite differences in the
urface phenotypes of injected cells, the observed equiv-
lent improvements in hind-limb blood ﬂow comparing
CB- and BM-derived EPCs may stem from the en-
anced expression of the CXCR-4 chemokine receptor
n EPCs derived from UCB on the one hand and in-
reased expression of stromal cell markers on BM-de-
ived EPCs on the other.
It is important to note that our studies directly com-
aring UCB- and BM-derived EPCs indicate that the
ells have equivalent functionality and demonstrate that
simple isolation technique, the collection of adherent
ells after 7 days of culture of whole MNCs, produces a
ell population with a functional vasculogenesis efﬁcacy
quivalent to that of BM-derived EPCs in the NOD/
CID vascular injury model. UCB has several advan-
ages over BM in potential applications, including UCB
ollection at no risk to the donor, greater accessibility for
torage, immediate availability in a bank, wider availabil-
ty of diverse HLA genotypes, and, importantly, a lower
athogen content. Particularly attractive is the wide
vailability of UCB, with 4 million live births every
ear in the United States alone; this would allow realistic
linical approaches using this stem cell source to treat
schemic cardiac disease, still a leading cause of death in
he United States [46].
Moreover, prior reports indicate that adult stem
ells, including hematopoietic, neural, mesenchymal,
nd cardiac stem cells, diminish in number and function
ith increasing age [47-50]. EPCs grown from the BM
f older patients may not yield consistently satisfactory
ell numbers for transplantation and neovascularization
or individual patient treatment. UCB has been shown to
ontain hematopoietic stem cells of higher proliferative
apacity than those from the BM of healthy donors [51]
nd has been used successfully in the treatment of he-
atologic disorders [52]. UCB may be considered an
lternative to BM in the cardiac clinical setting. Further
tudies are ongoing to determine the speciﬁc cell sub-
opulations with the highest EPC biologic function, the
elative contributions of direct cell-mediated versus
aracrine effects underlying neovascularization in re-
ponse to vascular injury, and the immunogenicity of
ells derived from UCB.
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